Drug intelligence / Profile preview

Anti-COVID-19 Immune Globulin (Human)

Development stage: Discontinued
Lead developer: Grifols
Modality: Recombinant Proteins and Enzymes, Antibody-Based Therapeutics
Administration: Subcutaneous

Overview

Anti-COVID-19 Immune Globulin (Human) is a 20% solution of human immune globulin, purified from the plasma of convalescent donors who have recovered from COVID-19. Developed by Grifols Therapeutics LLC, this biologic contains high titers of anti-SARS-CoV-2 antibodies. Its primary mechanism of action involves providing passive immunity by neutralizing the SARS-CoV-2 virus, thereby preventing viral entry into host cells. Additionally, it may exert immunomodulatory effects to mitigate inflammation associated with COVID-19. It was investigated for its efficacy in preventing symptomatic COVID-19 in asymptomatic outpatients infected with SARS-CoV-2.

Other names: anti-SARS-CoV-2 hyperimmune globulinanti-SARS-CoV2 hyperimmune globulinanti-SARS-CoV 2 hyperimmune globulinanti-SARS-CoV-2 hyperimmune immunoglobulinanti-SARS-CoV2 hyperimmune immunoglobulinanti-SARS-CoV 2 hyperimmune immunoglobulin

Targets

SARS-CoV-2 spikeFcγR (Low affinity immunoglobulin gamma Fc region receptor II-c)

Beyond the preview

Go deeper on Anti-COVID-19 Immune Globulin (Human).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Anti-COVID-19 Immune Globulin (Human).

Explore the full profile